AAP News Vol. 14 No. 8 August 1998, p. 16
© 1998 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerber, M.
Right arrow Articles by Weiner, L.
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Experts answer common questions about varicella vaccine

Michael Gerber M.D., FAAP and Leonard Weiner M.D., FAAP

Varicella vaccine is recommended for routine use in all healthy children age 12 months and older who lack a reliable history of varicella. More than 10 million doses of live attenuated varicella-zoster-virus (VZV) vaccine have been distributed in this country since it was licensed by the U.S. Food and Drug Administration in March 1995. However, many eligible children have not received VZV vaccine because some physicians have not encouraged its use. Michael Gerber, M.D., and Leonard Weiner, M.D., AAP Committee on Infectious Diseases members, offer the following responses to common questions about this vaccine.